Combination immunotherapy in hepatocellular carcinoma: synergies among immune checkpoints, TKIs, and chemotherapy.

J Hematol Oncol · 2025 · PMC12465164 · PMID 41013723

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

narrowly missed statistical significanceno p-value reported

However, in the Phase 3 LEAP-002 trial ( NCT03713593 ), the combination narrowly missed statistical significance compared to lenvatinib alone, likely due to unexpectedly strong outcomes in the control arm [ 59 ].

also in 104 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.